| 沈 静,张丽华,徐晶晶,吕萌萌,吴东辰.卡瑞利珠单抗联合白蛋白结合型紫杉醇对晚期宫颈癌患者肿瘤标志物、免疫功能和血管新生指标的影响[J].,2024,(13):2592-2595 |
| 卡瑞利珠单抗联合白蛋白结合型紫杉醇对晚期宫颈癌患者肿瘤标志物、免疫功能和血管新生指标的影响 |
| Effects of Carrelizumab Combined with Albumin-Bound Paclitaxel on Tumor Markers, Immune Function and Angiogenesis Indexes in Patients with Advanced Cervical Cancer |
| 投稿时间：2024-01-27 修订日期：2024-02-22 |
| DOI：10.13241/j.cnki.pmb.2024.13.037 |
| 中文关键词: 卡瑞利珠单抗 白蛋白结合型紫杉醇 晚期宫颈癌 肿瘤标志物 免疫功能 血管新生指标 |
| 英文关键词: Carrelizumab Albumin-bound paclitaxel Advanced cervical cancer Tumor markers Immune function Angiogenesis indexes |
| 基金项目:中国抗癌协会科研基金项目（CETSDHCORP252-3-016） |
|
| 摘要点击次数: 234 |
| 全文下载次数: 126 |
| 中文摘要: |
| 摘要 目的：观察卡瑞利珠单抗联合白蛋白结合型紫杉醇对晚期宫颈癌患者免疫功能、肿瘤标志物、血管新生指标的影响。方法：采用随机数字表法，将2019年6月到2023年6月徐州医科大学附属淮安医院、江苏省肿瘤医院、东南大学附属中大医院收治的93例晚期宫颈癌患者分为对照组（n=46，白蛋白结合型紫杉醇治疗）和观察组（n=47，卡瑞利珠单抗联合白蛋白结合型紫杉醇治疗）。对比两组疗效、肿瘤标志物、免疫功能指标、血管新生指标指标和不良反应情况。结果：观察组的客观缓解率（ORR）为44.68%，疾病控制率（DCR）为74.47%分别高于对照组的21.74%、50.00%（P<0.05）。治疗后，观察组鳞状细胞癌抗原（SCCA）、癌胚抗原（CEA）、糖类抗原（CA）125、CA199、血管生成素-2（Ang-2）、血管内皮生长因子（VEGF）、CD8+低于对照组，CD3+、CD4+、CD4+/CD8+高于对照组（P<0.05）。对照组不良反应总发生率为34.78%，观察组的为29.79%，组间对比未见差异（P>0.05）。结论：卡瑞利珠单抗联合白蛋白结合型紫杉醇可降低晚期宫颈癌患者肿瘤标志物水平，提高免疫功能，抑制肿瘤血管新生，有效阻止疾病进展。 |
| 英文摘要: |
| ABSTRACT Objective: To observe the effect of carrelizumab combined with albumin-bound paclitaxel on immune function, tumor markers and angiogenesis indexes in patients with advanced cervical cancer. Methods: According to the random number table method, 93 patients with advanced cervical cancer admitted to the Affiliated Huai'an Hospital of Xuzhou Medical University, Jiangsu Cancer Hospital and Zhongda Hospital Affiliated to Southeast University from June 2019 to June 2023 were divided into control group (n=46, albumin-bound paclitaxel treatment) and observation group (n=47, carrelizumab combine with albumin-bound paclitaxel treatment). The efficacy, tumor markers, immune function indexes, angiogenesis indexes and adverse reactions in two groups were compared. Results: The objective response rate (ORR) of the observation group was 44.68%, and the disease control rate (DCR) was 74.47%, which were higher than the control group's 21.74% and 50.00%, respectively(P<0.05). After treatment, the levels of squamous cell carcinoma antigen (SCCA), carcinoembryonic antigen (CEA), carbohydrate antigen (CA) 125, CA199, angiopoietin-2 (Ang-2), vascular endothelial growth factor (VEGF) and CD8+ in observation group were lower than those in control group, and the levels of CD3+, CD4+, CD4+/CD8+ were higher than those in control group (P<0.05). The total incidence of adverse reactions in control group was 34.78%, and that in observation group was 29.79%, there was no difference between two groups(P>0.05). Conclusion: Carrelizumab combined with albumin-bound paclitaxel can reduce the level of tumor markers in patients with advanced cervical cancer, improve immune function, inhibit tumor angiogenesis, and effectively prevent disease progression. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
